TG Therapeutics TGTX Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $442.21M+235% | $79.15M-56.0% | $74.08M-62.2% | $129.13M+55.7% | $132.14M+75.1% | ||
| $1.35M+3.8% | $1.34M+3.4% | $1.33M+2.6% | $1.32M+1.9% | $1.3M+1.0% | ||
| $392.05M+106% | $305.63M+137% | $265.38M+129% | $231.52M+177% | $190.12M+193% | ||
| $26.35M-83.3% | $15.69M— | $146.95M+73.6% | $155.2M+91.0% | $157.76M+103% | ||
| $51.46M+152% | $57.58M+266% | $55.85M+71.1% | $25.37M+260% | $20.39M+152% | ||
| $1.09B+68.7% | $630.76M+11.4% | $599.77M+4.5% | $663.96M+70.6% | $644.51M+78.7% | ||
| $6.48M-6.4% | $6.28M-12.2% | $6.5M-12.3% | $6.72M-12.3% | $6.93M-12.4% | ||
| $344.14M— | $348M— | $366.63M— | —— | $0— | ||
| $2.02M-1.3% | $2.04M-1.4% | $2.05M-3.3% | $2.03M-5.9% | $2.04M— | ||
| $61.54M+3,127% | $59.14M+7,219% | $48.76M+4,234% | $28.59M+2,919% | $1.91M+44.5% | ||
| $72.22M-49.9% | $62.82M-52.1% | $57.5M-60.4% | $122.74M-8.6% | $144.1M+7.3% | ||
| $1.53B+133% | $1.06B+84.1% | $1.03B+74.9% | $702.61M+75.1% | $656.69M+75.9% | ||
| $148.85M+11.1% | $107.51M+84.4% | $112.34M+10.8% | $134.02M+43.4% | $133.93M+53.5% | ||
| $596K-79.8% | $2.12M-54.1% | $1.99M-39.6% | $2.26M-45.8% | $2.95M-27.5% | ||
| $18.66M+263% | $21.85M+43.9% | $15.01M+48.9% | $10.61M+67.1% | $5.14M+42.7% | ||
| $6.86M+4.0% | $8.81M-27.1% | $8.35M-48.4% | $1.67M-55.5% | $6.6M+103% | ||
| $1.82M+63.3% | $1.04M-9.8% | $1.07M-13.2% | $1.09M-16.5% | $1.12M-19.3% | ||
| $187.11M+16.8% | $153.76M+69.6% | $156.81M+25.3% | $171.89M+58.2% | $160.21M+60.7% | ||
| $745.14M+204% | $245.65M+0.5% | $245.34M+0.5% | $245.04M+139% | $244.73M+142% | ||
| $6.6M-16.1% | $7.02M-13.7% | $7.31M-13.2% | $7.59M-12.7% | $7.86M-12.3% | ||
| $8.42M-6.2% | $8.07M-13.2% | $8.38M-13.2% | $8.68M-13.2% | $8.98M-13.2% | ||
| $945.71M+125% | $415.23M+16.9% | $417.81M+6.1% | $426.18M+90.6% | $419.4M+96.7% | ||
| $160K+0.6% | $159K+1.9% | $159K+1.9% | $159K+2.6% | $159K+2.6% | ||
| $1.85B+3.9% | $1.83B+4.0% | $1.81B+3.7% | $1.79B+3.5% | $1.78B+5.4% | ||
| -$1.06B+30.3% | -$1.08B+29.2% | -$1.11B+28.8% | -$1.5B+3.9% | -$1.52B+0.1% | ||
| $200.23M+1,225% | $100.23M+1,014% | $100.23M+4,106% | $21.99M+9,298% | $15.12M+6,360% | ||
| $583.13M+146% | $648.02M+191% | $607.22M+216% | $276.43M+55.7% | $237.29M+48.2% | ||
| $1.53B+133% | $1.06B+84.1% | $1.03B+74.9% | $702.61M+75.1% | $656.69M+75.9% | ||
| $51.46M+152% | $57.58M+266% | $55.85M+71.1% | $25.37M+260% | $20.39M+152% | ||
| $2.02M-1.3% | $2.04M-1.4% | $2.05M-3.3% | $2.03M-5.9% | $2.04M— | ||
| $6.48M-6.4% | $6.28M-12.2% | $6.5M-12.3% | $6.72M-12.3% | $6.93M-12.4% | ||
| $344.14M— | $348M— | $366.63M— | —— | —— | ||
| $61.54M+3,127% | $59.14M+7,219% | $48.76M+4,234% | $28.59M+2,919% | $1.91M+44.5% | ||
| $6.48M-6.4% | $6.28M-12.2% | $6.5M-12.3% | $6.72M-12.3% | $6.93M-12.4% | ||
| $2.02M-1.3% | $2.04M-1.4% | $2.05M-3.3% | $2.03M-5.9% | $2.04M— | ||
| $72.22M-49.9% | $62.82M-52.1% | $57.5M-60.4% | $122.74M-8.6% | $144.1M+7.3% | ||
| $6.48M-6.4% | $6.28M-12.2% | $6.5M-12.3% | $6.72M-12.3% | $6.93M-12.4% | ||
| $2.02M-1.3% | $2.04M-1.4% | $2.05M-3.3% | $2.03M-5.9% | $2.04M— | ||
| $148.85M+11.1% | $107.51M+84.4% | $112.34M+10.8% | $134.02M+43.4% | $133.93M+53.5% | ||
| $17.19M+0.6% | $21.23M+86.0% | $26.4M+190% | $23.91M+609% | $17.08M+406% | ||
| $596K-79.8% | $2.12M-54.1% | $1.99M-39.6% | $2.26M-45.8% | $2.95M-27.5% | ||
| $6.86M+4.0% | $8.81M-27.1% | $8.35M-48.4% | $1.67M-55.5% | $6.6M+103% | ||
| $753.56M+197% | $253.71M0.0% | $253.72M0.0% | $253.72M+125% | $253.71M+127% | ||
| $160K+0.6% | $159K+1.9% | $159K+1.9% | $159K+2.6% | $159K+2.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are TG Therapeutics's total assets?
- TG Therapeutics (TGTX) holds $1.5B in total assets, up 132.8% year over year.
- How much debt does TG Therapeutics have?
- TG Therapeutics carries $753.6M in total debt against $583.1M of shareholders' equity, a debt-to-equity ratio of 1.29.
- How much cash does TG Therapeutics have?
- TG Therapeutics holds $442.2M in cash and equivalents.
- Can TG Therapeutics cover its short-term obligations?
- Its current ratio is 5.81 — current assets exceed current liabilities.
- Where does TG Therapeutics's balance sheet data come from?
- Every line is extracted from TG Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
